At J.P. Morgan, Ironwood, Shire and Biogen Idec Contemplate What’s Next
A trio of companies offer insight into their latest strategies from interviews and presentations at the recent J.P. Morgan Healthcare conference: Ironwood’s development pipeline includes seven GI drugs; R&D consolidation and pipeline review at Shire; Biogen preps for hemophilia market and MS pricing pressures.
You may also be interested in...
FDA approves new oncology imaging agents and a long-acting hemophilia drug; Sanofi/Regeneron present positive Phase III on RA drug sarilumab; biosimilar infliximab shows no meaningful differences to Remicade; Imbruvica response rates improved with umblituximab; Cyramza fails survival endpoint in liver cancer.
FDA approves Biogen’s long-acting hemophilia drug Alprolix and lifts clinical hold on Curis’ cancer drug CUDC-427, but Amgen’s announcement that its melanoma vaccine T-VEC failed to improve survival clouds its chances with the agency.
While planning to split into two companies, one focused on its successful hemophilia franchise, Baxter fully acquires Phase I/II gene therapy program for hemophilia B. Baxter has been seeking ways to bolster its hemophilia business in the face of coming competition from the likes of Biogen Idec.